KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study Meeting Abstract
| Authors: | Chung, H. C.; Bang, Y. J.; Fuchs, C. S.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Alsina, M.; Cao, Z. A.; Chen, X.; Bhagia, P.; Shih, C. S.; Janjigian, Y. Y. |
| Abstract Title: | KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study |
| Meeting Title: | 2020 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000530922700444 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.4_suppl.TPS463 |
| Notes: | Meeting Abstract: TPS463 -- Source: Wos |
